Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Impact of Phosphate Metabolism on Healthy Aging
NCT03771105Phase 1Recruiting
- Sponsor
- Yale University
- Start
- Jan 2019
- Primary completion
- Apr 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1 trial of phosphate in X-linked hypophosphatemia (XLH) and hereditary hypophosphatemic rickets with hypercalciuria (HHRH) (4 arms), sponsored by Yale University. Primary endpoints: Parathyroid Hormone levels at 30 days and Fibroblast Growth Factor 23 levels at 30 days. Started Jan 2019; status: recruiting.
02
Drugs
phosphate
03
Conditions
X-linked hypophosphatemia (XLH)hereditary hypophosphatemic rickets with hypercalciuria (HHRH)
Beyond the preview
Go deeper on NCT03771105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03771105.